Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418450

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what criteria NICE has set for new dementia treatments to be recommended for provision by the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10022
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The National Institute for Health and Care Excellence assesses significant new drugs and treatments, including those for the treatment of dementia, through its technology appraisal programme. Technology appraisals are conducted in accordance with NICE’s <em>Guide to the methods of technology appraisal 2013</em> which is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/Foreword" target="_blank">www.nice.org.uk/article/pmg9/chapter/Foreword</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:15:57 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

418451

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his policies of the decision by NHS England announced on 4 September 2015 to remove (a) the pancreatic cancer drug Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10091
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>No such assessment has been made. We remain committed to continuing to invest in the Cancer Drugs Fund which has so far benefitted over 72,000 people with cancer in England.</p><p> </p><p> </p><p> </p><p>We understand that NHS England continues to work with manufacturers seeking to maintain drug and indication combinations within the Fund.</p><p> </p><p><strong> </strong></p><p> </p><p>NHS England has confirmed that patients who are already receiving a drug/indication which is to be removed from the Fund will continue to be treated with that drug until they and their clinicians consider it appropriate to discontinue treatment. In addition, drugs removed from the Fund will continue to be available via Individual Funding Requests if the individual patient meets clinical exceptionality criteria.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:22:40 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418455

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the final results of the National Institute for Health Research's ProtecT trials for prostate cancer testing to be published; and if he will make a statement.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	9996
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The ProtecT randomised controlled trial is evaluating the effectiveness, cost-effectiveness and acceptability of active monitoring, radical 3D conformal radiotherapy and radical prostatectomy in men with clinically localised prostate cancer, identified through population-based PSA (Prostate Specific Antigen) testing.</p><p> </p><p> </p><p> </p><p>There have already been over 100 published outputs from ProtecT and these are listed on the National Institute for Health Research (NIHR) website:</p><p> </p><p> </p><p> </p><p>www.nets.nihr.ac.uk/projects/hta/962099</p><p> </p><p> </p><p> </p><p>The researchers plan to publish the primary and most secondary analyses during 2016 at major relevant conferences and in peer-reviewed journals. The primary outcome to be evaluated is definite or probable prostate cancer specific mortality at a median of 10 years following randomisation. A monograph covering these findings is expected to be published in the NIHR Journals Library in July 2017. Findings from longer term follow-up will be published at a later stage.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:17:51 answering member 4020 label Biography information for George Freeman
tabling member	1409 label Biography information for Mr Gregory Campbell

418458

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the effect of eye clinic liaison officers on improving patient health and social care; and what progress he has made on increasing the provision of such officers.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	9980
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Government fully appreciates the impact that sight loss can have on a person’s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.</p><p> </p><p> </p><p> </p><p>Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 9977 question first answered 16/09/2015 12:01:58 answering member 1201 label Biography information for Alistair Burt
tabling member	253 label Biography information for Mr Laurence Robertson

418459

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what funding his Department provides for eye clinic liaison officers.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	9977
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Government fully appreciates the impact that sight loss can have on a person’s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.</p><p> </p><p> </p><p> </p><p>Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 9980 question first answered 16/09/2015 12:01:58 answering member 1201 label Biography information for Alistair Burt
tabling member	253 label Biography information for Mr Laurence Robertson

418462

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Suicide: Males
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect of family separation on male suicide rates.
tabling member constituency	Newcastle upon Tyne East
tabling member printed	Mr Nicholas Brown
uin	9993
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>No such assessment has been made, however we know that there are links between mental ill health and social factors like isolation and family breakdown and that men in certain age-groups are more likely to present with suicidal behaviour. Suicide continues to be more than three times as common in males than in females, 13.8 per 100,000 for males in 2011-13, compared to 4.0 for females.</p><p> </p><p><em> </em></p><p> </p><p><em>Preventing suicide in England: A cross-government outcomes strategy to save lives</em>, published in 2012, identified a number of high risk groups who are priorities for prevention young and middle-aged men. The strategy recognises that factors associated with suicide in men include family and relationship problems including marital breakup and social isolation. The strategy recognises that those who work with men in different settings, especially primary care, need to be particularly alert to the signs of suicidal behaviour.</p><p> </p><p> </p><p> </p><p>A review by the Samaritans, <em>Men Suicide and Society</em>, published in 2012, also highlighted that middle-aged men in certain socioeconomic groups are at particularly high risk of suicide. It pointed to evidence that suicidal behaviour results from the interaction of complex factors, including a lack of close social and family relationships, personal crises such as divorce, as well as a general ‘dip’ in subjective wellbeing among people in their mid-years, compared to both younger and older people. The report also found that relationship breakdown is more likely to lead men, rather than women, to suicide and was published in February 2015.</p><p> </p><p> </p><p> </p><p>The Government’s first annual report on the suicide prevention strategy was published on 17 January 2014. It highlighted a new agreement designed to promote greater sharing of information with friends and family of people at risk of suicide. The second annual report into suicide prevention was written for people working in local services.</p><p> </p><p> </p><p> </p><p>In January 2015, this Government called for every part of the National Health Service to commit to a 'zero suicide' ambition to dramatically reduce suicides. This goes beyond health service boundaries into the whole community, bringing in the police, education, housing, debt support services and so on.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 16/09/2015 12:07:20 answering member 1201 label Biography information for Alistair Burt
tabling member	523 label Biography information for Mr Nicholas Brown

418463

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps NHS England takes to assess the health and social care needs of patients with hidradenitis suppurativa; and what assessment he has made of the ability of the NHS to deliver efficient diagnosis and access to specialist care for such patients.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	10010
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10011 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

418464

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress has been made by NHS England on the production of a commissioning policy for treatments associated with hidradenitis suppurativa; what the proposed scope of that policy is; and when he expects that policy to have been fully developed.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	10011
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10010 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

417652

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with NHS England on recent guidance stating that NICE-recommended medicines will be funded from day 90 of publication.
tabling member constituency	Islington South and Finsbury
tabling member printed	Emily Thornberry
uin	9350
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>No such discussions have taken place.</p><p> </p><p> </p><p> </p><p>Commissioners are legally required to provide funding for treatments and drugs recommended in National Institute for Health and Care Excellence (NICE) technology appraisal guidance within three months of NICE’s final guidance.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 14:54:33 answering member 4020 label Biography information for George Freeman
tabling member	1536 label Biography information for Emily Thornberry

417654

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent progress NHS England has made on developing new policies for in-year service developments and individual funding requests; and if NHS England will commit to a public consultation on these matters.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	9346
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England is in the process of concluding a review of these two policies and is aiming to finalise the way forward, including a position on public consultation, by the end of September.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:03:56 answering member 4020 label Biography information for George Freeman
tabling member	104 label Biography information for Crispin Blunt